Skip to main content
SpringerLink
Log in

Monoclonal Antibody Therapy of Cancer

  • Chapter
General Principles of Tumor Immunotherapy

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495–497.

    Article  PubMed  Google Scholar 

  2. Burrows PD, Cooper MD. B-cell development in man. Curr Opin Immunol 1993; 5:201–206.

    Article  PubMed  CAS  Google Scholar 

  3. Petersen JG, Dorrington KJ. An in vitro system for studying the kinetics of interchain disulfide bond formation in immunoglobulin G. J Biol Chem 1974; 249:5633–5641.

    PubMed  CAS  Google Scholar 

  4. Welling GW, Geurts T, van Gorkum J, et al. Synthetic antibody fragment as ligand in immunoaffinity chromatography. J Chromatogr 1990; 512:337–343.

    Article  PubMed  CAS  Google Scholar 

  5. Segal DM, Wunderlich JR. Targeting of cytotoxic cells with heterocrosslinked antibodies. Cancer Invest 1988; 6:83–92.

    PubMed  CAS  Google Scholar 

  6. Meeker TC, Lowder J, Maloney DG, et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985; 65:1349–1363.

    PubMed  CAS  Google Scholar 

  7. Senter PD. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. FASEB J 1990; 4:188–193.

    PubMed  CAS  Google Scholar 

  8. Yuan F, Baxter LT, Jain RK. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res 1991; 51:3119–3130.

    PubMed  CAS  Google Scholar 

  9. Pastan I, FitzGerald D. Recombinant toxins for cancer treatment. Science 1991; 254:1173–1177.

    Article  PubMed  CAS  Google Scholar 

  10. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345:241–247.

    Article  PubMed  CAS  Google Scholar 

  11. Grossbard ML, Lambert JM, Goldmacher VS, et al. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 1993; 11:726–737.

    PubMed  CAS  Google Scholar 

  12. Duzkale H, Pagliaro LC, Rosenblum MG, et al. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel. Biol Blood Marrow Transplant 2003; 9:364–372.

    Article  PubMed  CAS  Google Scholar 

  13. Talpaz M, Kantarjian H, Freireich E, et al. Phase I clinical trial of the anti-CD33-immunotoxin HuM195/rGel. Proc Am Assoc Cancer Res 2003; 44:1228.

    Google Scholar 

  14. Scheinberg DA, Straus DJ, Yeh SD, et al. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin’s lymphoma: effects of tumor burden and antigen expression. J Clin Oncol 1990; 8:792–803.

    PubMed  CAS  Google Scholar 

  15. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329:1219–1224.

    Article  PubMed  CAS  Google Scholar 

  16. Williams LE, Duda RB, Proffitt RT, et al. Tumor uptake as a function of tumor mass: a mathematic model. J Nucl Med 1988; 29:103–109.

    PubMed  CAS  Google Scholar 

  17. Fujimori K, Covell DG, Fletcher JE, et al. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990; 31:1191–1198.

    PubMed  CAS  Google Scholar 

  18. Juweid M, Neumann R, Paik C, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992; 52:5144–5153.

    PubMed  CAS  Google Scholar 

  19. Scheinberg DA, Lovett D, Divgi CR, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol, 1991;9(3):478–90.

    PubMed  CAS  Google Scholar 

  20. Appelbaum FR, Matthews DC, Eary JF, et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992; 54:829–833.

    Article  PubMed  CAS  Google Scholar 

  21. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329:459–465.

    Article  PubMed  CAS  Google Scholar 

  22. Caron PC, Co MS, Bull MK, et al. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res, 1992;52(24):6761–7.

    PubMed  CAS  Google Scholar 

  23. Riechmann L, Clark M, Waldmann H, et al. Reshaping human antibodies for therapy. Nature, 1988;332(6162):323–7.

    Article  PubMed  CAS  Google Scholar 

  24. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A, 1992;89(10):4285–9.

    Article  PubMed  CAS  Google Scholar 

  25. Gram H, Marconi LA, Barbas CF, 3rd, et al. In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. Proc Natl Acad Sci U S A, 1992;89(8):3576–80.

    Article  PubMed  CAS  Google Scholar 

  26. Junghans RP. Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res 1997;16(1):29–57.

    PubMed  CAS  Google Scholar 

  27. Green LL, Hardy MC, Maynard-Currie CE, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet, 1994;7(1):13–21.

    Article  PubMed  CAS  Google Scholar 

  28. Ishida I, Tomizuka K, Yoshida H, et al. Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells, 2002;4(1):91–102.

    Article  PubMed  CAS  Google Scholar 

  29. Nikula TK, Bocchia M, Curcio MJ, et al. Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity. Mol Immunol 1995; 32:865–872.

    Article  PubMed  CAS  Google Scholar 

  30. Jurcic JG, Divgi CR, McDevitt MR, et al. Potential for myeloablation with Yttrium-90-HuM195 (anti-CD33) in myeloid leukemia. Proc Am Soc Clin Oncol, 2000: 19:8a.

    Google Scholar 

  31. Scheinberg DA, Strand M. Kinetic and catabolic considerations of monoclonal antibody targeting in erythroleukemic mice. Cancer Res 1983; 43:265–272.

    PubMed  CAS  Google Scholar 

  32. Lovqvist A, Humm JL, Sheikh A, et al. PET imaging of 86Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between 86Y and 111In radiolabels. J Nucl Med 2001; 42:1281–1287.

    PubMed  CAS  Google Scholar 

  33. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998; 25:1341–1351.

    Article  PubMed  CAS  Google Scholar 

  34. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100:1233–1239.

    PubMed  CAS  Google Scholar 

  35. Mulford DA, Pandit-Taskar N, McDevitt MR, et al. Sequential therapy with cytarabine and bismuth-213 (213Bi)-labeled HuM195 (anti-CD33) for acute myeloid leukemia (AML). Blood 2004; 104:496a.

    Google Scholar 

  36. Zalutsky MR, Narula AS. Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate. Int J Rad Appl Instrum [A] 1988; 39:227–232.

    Article  CAS  Google Scholar 

  37. Zalutksy M, Reardon D, Akabani G, et al. Astatine-211 labeled human/mouse chimeric anti-tenascin monoclonal antibody via surgically created resection davities for patients with recurrent glioma: phase I study. Neuro-oncol 2202; 4(suppl):S103.

    Google Scholar 

  38. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001; 294:1537–1540.

    Article  PubMed  CAS  Google Scholar 

  39. Sgouros G. Dosimetry of internal emitters. J Nucl Med 2005; 46:18S-27S.

    PubMed  Google Scholar 

  40. Humm JL, Roeske JC, Fisher DR, Chen GTY. Microdosimetric concepts in radioimmunotherapy. Med Phys 1993; 20:535–543.

    Article  PubMed  CAS  Google Scholar 

  41. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA 2000; 97:1802–1807.

    Article  PubMed  CAS  Google Scholar 

  42. Zhang M, Zhang Z, Garmestani K, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the α-emitting radionuclide, bismuth 213. Blood 2002; 100:208–216.

    Article  PubMed  CAS  Google Scholar 

  43. Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA 2003; 100:1891–1895.

    Article  PubMed  CAS  Google Scholar 

  44. Forero A, Weiden PL, Vose JM, et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 2004; 104:227–236.

    Article  PubMed  CAS  Google Scholar 

  45. Shen S, Forero A, LoBulgio AF, et al. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med 2005; 46:642–651.

    PubMed  CAS  Google Scholar 

  46. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825–2833.

    PubMed  CAS  Google Scholar 

  47. Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma—a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23:1088–1095.

    Article  PubMed  CAS  Google Scholar 

  48. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17:268–276.

    PubMed  CAS  Google Scholar 

  49. Marcus R, Imrie K, Belch A, et al. An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkin’s lymphoma. Blood 2003; 102:28a.

    Google Scholar 

  50. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235–242.

    Article  PubMed  CAS  Google Scholar 

  51. Coiffier B, Herbrecht R, Tilly H, et al. GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3-year median follow-up with an analysis according to co-morbidity factors. Proc Am Soc Clin Oncol, 2003; 22:596.

    Google Scholar 

  52. Habermann T, Weller E, Morrison V. Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 102:6a.

    Google Scholar 

  53. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18:317–324.

    PubMed  CAS  Google Scholar 

  54. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1998; 9:995–1001.

    Article  PubMed  CAS  Google Scholar 

  55. Nguyen DT, Amess JA, Doughty H, et al. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin’s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999; 62:76–82.

    Article  PubMed  CAS  Google Scholar 

  56. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19:2153–2164.

    PubMed  CAS  Google Scholar 

  57. O’Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19:2165–2170.

    PubMed  CAS  Google Scholar 

  58. Wierda W, O’Brien SM, Faderl S, et al. Improved survival in patients with relapsed- refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination. Blood 2003; 102:110a.

    Google Scholar 

  59. Weiss M, Lamanna N, Jurcic J, et al. Pentostatin, cyclophosphamide, and rituximab (PCR therapy): a new active regimen for previously treated patients with chronic lymphocytic leukemia (CLL). Blood 2003; 102:673a.

    Article  Google Scholar 

  60. Hale G, Dyer MJ, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2:1394–1399.

    Article  PubMed  CAS  Google Scholar 

  61. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99:3554–3561.

    Article  PubMed  CAS  Google Scholar 

  62. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100:768–773.

    Article  PubMed  CAS  Google Scholar 

  63. Wierda W, Faderl S, O’Brien S, et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL. Blood 2004; 104:101a.

    Google Scholar 

  64. Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002; 20:205–213.

    Article  PubMed  CAS  Google Scholar 

  65. Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001; 98:1721–1726.

    Article  PubMed  CAS  Google Scholar 

  66. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104:3865–3871.

    Article  PubMed  CAS  Google Scholar 

  67. Chakrabarti S, MacDonald D, Hale G, et al. T-cell depletion with Campath-1H ‘in the bag’ for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haemat 2003; 121:109–118.

    Article  Google Scholar 

  68. Nahta R, Esteva FJ. HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 2003; 9:5078–5084.

    PubMed  CAS  Google Scholar 

  69. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14:737–744.

    PubMed  CAS  Google Scholar 

  70. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639–2648.

    PubMed  CAS  Google Scholar 

  71. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783–792.

    Article  PubMed  CAS  Google Scholar 

  72. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:1800–1808.

    Article  PubMed  CAS  Google Scholar 

  73. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335–2342.

    Article  PubMed  CAS  Google Scholar 

  74. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427–434.

    Article  PubMed  CAS  Google Scholar 

  75. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337–345.

    Article  PubMed  CAS  Google Scholar 

  76. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201–1208.

    Article  PubMed  CAS  Google Scholar 

  77. Baselga J, Trigo J, Bouthis J. Cetuximab (C225) plus cisplatin/carboplatin is active in patients with recurrent/metastatic squamous-cell carcinoma of the head and neck progressing on a same dose and schedule platinum-based regimen. Proc Am Soc Clin Oncol 2002; 21:226a.

    Google Scholar 

  78. Burtness BA, Li Y, Flood W, et al. Phase III trial comparing cisplatin (C) + placebo to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients with metastatic/recurrent head & neck cancer (HNC). Proc Am Soc Clin Oncol 2002; 21:226a.

    Google Scholar 

  79. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999; 93:3678–3684.

    PubMed  CAS  Google Scholar 

  80. Sievers EL, Larson RA, Staudtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19:3244–3254.

    PubMed  CAS  Google Scholar 

  81. Adadori S, Suciu Willemze R, et al. Sequential administration of gemtuzumab ozogamcin and convential chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Hematologica 2004; 89:950–956.

    Google Scholar 

  82. Sievers E, Larson R, Estey E, et al. Final report of prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin followed by hematpoietic stem cell transplantation. Blood 2002; 100:89a.

    Article  Google Scholar 

  83. Rajvanshi P, Schulman H, Sievers E, et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002; 99:10–14.

    Article  Google Scholar 

  84. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92:406–413.

    Article  PubMed  CAS  Google Scholar 

  85. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003; 102:4277–4283.

    Article  PubMed  CAS  Google Scholar 

  86. Estey E, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamicin (“Mylotarg”) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99:4222–4224.

    Article  PubMed  CAS  Google Scholar 

  87. Schwartz MA, Lovett DR, Redner A, et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 11:294–303.

    Google Scholar 

  88. Burke JM, Caron PC, Papadopoulos EB, et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advance myeloid leukemias. Bone Marrow Transplant 2003; 32:549–556.

    Article  PubMed  CAS  Google Scholar 

  89. Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 94:1237–1247.

    PubMed  CAS  Google Scholar 

  90. Pagel JM, Appelbaum FR, Eary JF, et al. 131I-anti-CD45 antibody plus busulfan/cyclophosphamide in matched related transplants for acute myeloid leukemia in first remission. Blood 2004; 104:232a.

    Google Scholar 

  91. Bunjes D. 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leuk Lymph 2002; 43:2125–2131.

    Article  CAS  Google Scholar 

  92. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2001; 19:3918–3928.

    PubMed  CAS  Google Scholar 

  93. Kaminski MS, Tuck M,m Estes J, et al. 131I tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352:441–449.

    Article  PubMed  CAS  Google Scholar 

  94. Press OW, Unger JM, Braziel RM, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositomomab for previously untreated follicular non-Hodgkin’s lymphoma: Southwest Oncology Group protocol S9911.

    Google Scholar 

  95. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998; 16:3270–3278.

    PubMed  CAS  Google Scholar 

  96. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96:2934–2942.

    PubMed  CAS  Google Scholar 

  97. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99:3158–3162.

    Article  PubMed  CAS  Google Scholar 

  98. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103:4429–4431.

    Article  PubMed  CAS  Google Scholar 

  99. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20:2453–2463.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021

    Joseph G. Jurcic, Deborah A. Mulford & David A. Scheinberg

Authors
  1. Joseph G. Jurcic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deborah A. Mulford
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David A. Scheinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY

    Howard L. Kaufman

  2. Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY

    Jedd D. Wolchok

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer

About this chapter

Cite this chapter

Jurcic, J.G., Mulford, D.A., Scheinberg, D.A. (2007). Monoclonal Antibody Therapy of Cancer. In: Kaufman, H.L., Wolchok, J.D. (eds) General Principles of Tumor Immunotherapy. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6087-8_14

Download citation

Publish with us

Policies and ethics

Search

Navigation